Nucleotide Novellas: Tessera Therapeutics撰写基因药物来治疗疾病

Q4 Biochemistry, Genetics and Molecular Biology Genetic Engineering & Biotechnology News Pub Date : 2023-02-01 DOI:10.1089/gen.43.02.02

Jonathan D. Grinstein

{"title":"Nucleotide Novellas: Tessera Therapeutics撰写基因药物来治疗疾病","authors":"Jonathan D. Grinstein","doi":"10.1089/gen.43.02.02","DOIUrl":null,"url":null,"abstract":"Genetic Engineering & Biotechnology NewsVol. 43, No. 2 GENEDGENucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure DiseasesThe Flagship Pioneering company has operationalized mobile genetic elements to make small and large permanent alterations to the human genomeJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:10 Feb 2023https://doi.org/10.1089/gen.43.02.02AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 2Feb 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases.Genetic Engineering & Biotechnology News.Feb 2023.10-11.http://doi.org/10.1089/gen.43.02.02Published in Volume: 43 Issue 2: February 10, 2023PDF download","PeriodicalId":50425,"journal":{"name":"Genetic Engineering & Biotechnology News","volume":"228 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases\",\"authors\":\"Jonathan D. Grinstein\",\"doi\":\"10.1089/gen.43.02.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Genetic Engineering & Biotechnology NewsVol. 43, No. 2 GENEDGENucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure DiseasesThe Flagship Pioneering company has operationalized mobile genetic elements to make small and large permanent alterations to the human genomeJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:10 Feb 2023https://doi.org/10.1089/gen.43.02.02AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 2Feb 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases.Genetic Engineering & Biotechnology News.Feb 2023.10-11.http://doi.org/10.1089/gen.43.02.02Published in Volume: 43 Issue 2: February 10, 2023PDF download\",\"PeriodicalId\":50425,\"journal\":{\"name\":\"Genetic Engineering & Biotechnology News\",\"volume\":\"228 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genetic Engineering & Biotechnology News\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/gen.43.02.02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic Engineering & Biotechnology News","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/gen.43.02.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

摘要

基因工程与生物技术新闻卷。43、No. 2 genedgenednucleotide Novellas:Tessera Therapeutics撰写治疗疾病的遗传药物旗舰先驱公司已经操作移动遗传元素，对人类基因组进行或大或大的永久性改变jonathan D. GrinsteinJonathan D. grinstein搜索本文作者的更多论文出版在线:2023年2月10日https://doi.org/10.1089/gen.43.02.02AboutSectionsView文章查看全文pdf /EPUB权限和引文spermissionsdownload引文strack引文添加到收藏回到出版ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails Volume 43Issue 2Feb 2023信息©2023 by GEN publishing引用本文:Jonathan D. Grinstein。Nucleotide Novellas: Tessera Therapeutics撰写基因药物来治疗疾病。基因工程与生物技术新闻。2023.10-11.http://doi.org/10.1089/gen.43.02.02Published in Volume: 43 Issue 2: February 10, 2023PDF下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases

Genetic Engineering & Biotechnology NewsVol. 43, No. 2 GENEDGENucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure DiseasesThe Flagship Pioneering company has operationalized mobile genetic elements to make small and large permanent alterations to the human genomeJonathan D. GrinsteinJonathan D. GrinsteinSearch for more papers by this authorPublished Online:10 Feb 2023https://doi.org/10.1089/gen.43.02.02AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 2Feb 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D. Grinstein.Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases.Genetic Engineering & Biotechnology News.Feb 2023.10-11.http://doi.org/10.1089/gen.43.02.02Published in Volume: 43 Issue 2: February 10, 2023PDF download

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.

期刊最新文献

Organoids Deliver True-to-Life Performances CRISPR-Edited Silkworms Spin Spider Silk Tougher Than Kevlar Multiomics in Pancreatic Cancer: A Conversation with Dr. William Hwang The Future of Personalized Medicine: Leveraging Customization for Faster Insights NGS Sample Prep: Enduring Basics and Evolving Enzyme Kits